Moringa Acquisition Corp. (MACA) to Combine with Silexion in $62M Deal

Moringa Acquisition Corp. (MACA) to Combine with Silexion in $62M Deal

Moringa (NASDAQ:MACA) has entered into a definitive agreement to combine with clinical-stage biotech firm Silexion at a pre-transaction equity value of $62.5 million. Modiā€™in-Maccabim-Reut, Israel-based Silexion is developing a range of potential cancer treatments with its most advanced efforts targeting pancreatic cancer. The combined company is expected to trade on the Nasdaq once the deal
Read More

To access this post, you must purchase 1 - User: Monthly Plan.